ATRIVA THERAPEUTICS GMBH has a total of 30 patent applications. It increased the IP activity by 1000.0%. Its first patent ever was published in 2001. It filed its patents most often in Australia, United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are QU BIOLOG INC, JAFFE RUSSELL and OMTHERA PHARMACEUTICALS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 5 | |
#2 | United States | 5 | |
#3 | WIPO (World Intellectual Property Organization) | 5 | |
#4 | Canada | 3 | |
#5 | China | 3 | |
#6 | EPO (European Patent Office) | 3 | |
#7 | Republic of Korea | 2 | |
#8 | Brazil | 1 | |
#9 | EAPO (Eurasian Patent Organization) | 1 | |
#10 | Japan | 1 | |
#11 | Luxembourg | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Environmental technology | |
#5 | Foods and drinks |
# | Name | Total Patents |
---|---|---|
#1 | Ludwig Stephan | 20 |
#2 | Planz Oliver | 17 |
#3 | Ehrhardt Christina | 9 |
#4 | Pleschka Stephan | 3 |
#5 | Oliver Planz | 3 |
#6 | Stephan Ludwig | 3 |
#7 | Stephan Pleschka | 2 |
#8 | Ewess Hazem | 1 |
Publication | Filing date | Title |
---|---|---|
WO2021069486A1 | Mek inhibitors for the treatment of hantavirus infections | |
WO2021037956A1 | Combinations of mek inhibitors with cap-dependent endonuclease inhibitors | |
WO2020188034A1 | Rsk inhibitors in the treatment of virus diseases | |
LU101183B1 | Novel mek-inhibitor for the treatment of viral and bacterial infections | |
US2019298669A1 | Ci-1040 for the treatment of viral diseases | |
CA3078424A1 | Novel mek-inhibitor for the treatment of viral and bacterial infections | |
AU2018202283A1 | Ci-1040 for the treatment of viral diseases | |
CA2999670A1 | Ci-1040 for the treatment of viral diseases | |
AU2015260765A1 | Novel anti-infective strategy against influenza virus and S. aureus coinfections |